← Back to Search

Deep Brain Stimulation

Deep Brain Stimulation for Obsessive-Compulsive Disorder

N/A
Waitlist Available
Led By Darin D Dougherty, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age between 21 and 65 years
Be older than 18 years old
Must not have
Pregnancy and women of childbearing age not using effective contraception
Any current clinically significant neurological disorder or medical illness affecting brain function, other than tic disorders or Tourette syndrome
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial uses a device that sends electrical signals to the brain to help patients with severe OCD who haven't responded to other treatments. It works by correcting abnormal brain activity and also records data to help researchers understand the treatment better. Deep brain stimulation (DBS) is an innovative treatment for severe obsessive-compulsive disorder (OCD).

Who is the study for?
Adults aged 21-65 with severe OCD, not improved after multiple treatments including drugs and behavioral therapy, can join this trial. They must be in good health, understand the study, consent to it, have a supportive family member or friend, and live near the study site. Excluded are those with psychotic disorders, low IQ/cognitive impairments affecting consent ability, bipolar disorder history, MRI contraindications like metal implants or claustrophobia.
What is being tested?
The Medtronic PC+S deep brain stimulation device is being tested as a treatment for patients with intractable OCD. This involves surgical implantation of electrodes into specific brain areas to modulate activity through electrical impulses.
What are the potential side effects?
Potential side effects may include discomfort at the implant site, headache following surgery or stimulation adjustments; risk of infection; possible changes in mood or behavior; and rarely bleeding inside the brain.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 21 and 65 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant and if of childbearing age, I use effective contraception.
Select...
I do not have any brain-affecting illnesses except for tic disorders or Tourette syndrome.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Yale-Brown Obsessive-Compulsive Scale (YBOCS)
Secondary study objectives
Clinical Global Impressions (CGI) Severity and Change scale
Montgomery-Asberg Depression Rating Scale (MADRS)
Patient Global Impressions (PGI) scale

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Medtronic Percept Deep Brain StimulationExperimental Treatment1 Intervention
Single open label arm. Patients with severe, treatment-refractory obsessive-compulsive disorder (OCD) will receive stimulation in two separate, but related, brain regions, the dorsolateral prefrontal cortex (dlPFC) and the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) with a novel Medtronic Percept deep brain stimulation (DBS) system.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Obsessive-Compulsive Disorder (OCD) include pharmacological therapies like selective serotonin reuptake inhibitors (SSRIs) and neuromodulation therapies such as Deep Brain Stimulation (DBS). SSRIs work by increasing serotonin levels in the brain, which helps alleviate OCD symptoms. DBS involves the implantation of electrodes that deliver electrical impulses to specific brain areas to regulate abnormal activity. This is crucial for patients with treatment-resistant OCD, providing an alternative when conventional treatments are ineffective.

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
3,014 Previous Clinical Trials
13,309,429 Total Patients Enrolled
26 Trials studying Obsessive-Compulsive Disorder
1,630 Patients Enrolled for Obsessive-Compulsive Disorder
Darin D Dougherty, MDPrincipal InvestigatorMassachusetts General Hospital
5 Previous Clinical Trials
110 Total Patients Enrolled
4 Trials studying Obsessive-Compulsive Disorder
50 Patients Enrolled for Obsessive-Compulsive Disorder

Media Library

Medtronic PC+S Deep Brain Stimulation (Deep Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT03184454 — N/A
Obsessive-Compulsive Disorder Research Study Groups: Medtronic Percept Deep Brain Stimulation
Obsessive-Compulsive Disorder Clinical Trial 2023: Medtronic PC+S Deep Brain Stimulation Highlights & Side Effects. Trial Name: NCT03184454 — N/A
Medtronic PC+S Deep Brain Stimulation (Deep Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03184454 — N/A
~0 spots leftby Oct 2025